Cellyan Biotechnology Co., Ltd (HKPD) vs NewcelX Ltd. (NCEL)
A side-by-side comparison of Cellyan Biotechnology Co., Ltd and NewcelX Ltd. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
HKPD
Cellyan Biotechnology Co., Ltd
$0.10HealthcareDelayed quote: Oct 6, 2026, 12:27 PM EDT
NCEL
NewcelX Ltd.
$2.95HealthcareDelayed quote: Oct 6, 2026, 11:58 AM EDT
Total return — HKPD vs NCEL
growth of $100 · dividends reinvested · last 2yHKPD -96.3% (-80.8%/yr)NCEL -85.9% (-62.5%/yr)NCEL compounded faster over this window
HKPD NCEL
HKPD vs NCEL: by the numbers
- •NCEL is the larger company ($1M vs $1M market cap).
- •Both run net losses; NCEL's is the smaller (0.00% vs -8.46% net margin).
Metrics side by side
Valuation
| Metric | HKPD | NCEL |
|---|---|---|
| P/B ratio | 0.11 | 0.22 |
Profitability
| Metric | HKPD | NCEL |
|---|---|---|
| Gross margin | 10.32% | 0.00% |
| Operating margin | -7.41% | 0.00% |
| Net margin | -8.46% | 0.00% |
| ROE | -11.85% | -114.48% |
| ROIC | -9.45% | -32.53% |
Growth (annualized)
| Metric | HKPD | NCEL |
|---|---|---|
| Total return CAGR (5Y) | N/A | -68.96% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.